Document is current
Any future updates will be listed below
-
Authors
Feringa, Femke M.
Koppes-den Hertog, Sascha J. https://orcid.org/0000-0002-7372-8946
Wang, Lian Y. https://orcid.org/0009-0006-0509-6680
Derks, Rico J. E. https://orcid.org/0000-0002-8920-7133
Kruijff, Iris
Erlebach, Lena https://orcid.org/0000-0002-9077-8689
Heijneman, Jorin
Miramontes, Ricardo
Pömpner, Nadine
Blomberg, Niek
Olivier-Jimenez, Damien https://orcid.org/0000-0002-6363-0857
Johansen, Lill Eva https://orcid.org/0000-0003-2187-6709
Cammack, Alexander J.
Giblin, Ashling
Toomey, Christina E. https://orcid.org/0000-0002-5146-3326
Rose, Indigo V. L. https://orcid.org/0000-0003-0491-1269
Yuan, Hebao
Ward, Michael E.
Isaacs, Adrian M.
Kampmann, Martin https://orcid.org/0000-0002-3819-7019
Kronenberg-Versteeg, Deborah
Lashley, Tammaryn
Thompson, Leslie M.
Ori, Alessandro https://orcid.org/0000-0002-3046-0871
Mohammed, Yassene https://orcid.org/0000-0003-3265-3332
Giera, Martin https://orcid.org/0000-0003-1684-1894
van der Kant, Rik https://orcid.org/0000-0002-7023-0106
- License Information
-
More Information
Article History
Received: 29 July 2024
Accepted: 5 August 2025
First Online: 22 September 2025
Competing interests
: R.K. has acted as a consultant for NewAmsterdam Pharma. M.K. is a coscientific founder of Montara Therapeutics, serves on the scientific advisory boards of Engine Biosciences, Casma Therapeutics, Cajal Neuroscience, Alector and Montara Therapeutics and is an advisor to Modulo Bio and Recursion Therapeutics. M.G. is a consultant to Boehringer-Ingelheim Pharma and an inventor of patent application WO2023172132A1. The other authors declare no competing interests.
